Human Heredity and Health in Africa (H3Africa): Coordinating Center (U24)

The summary for the Human Heredity and Health in Africa (H3Africa): Coordinating Center (U24) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Human Heredity and Health in Africa (H3Africa): Coordinating Center (U24): The purpose of this FOA is to solicit applications from foreign institutions in African countries to provide an Administrative Coordinating Center for the H3Africa Consortium. H3Africa research projects employ state of the art genomics approaches to study genetic and environmental contributors to specific health condition(s) or disease(s) relevant to African populations. The H3Africa Administrative Coordinating Center will provide the organizational framework for the management, direction, and overall coordination of all common H3Africa activities (i.e. Consortium activities).

Federal Grant Title:	Human Heredity and Health in Africa (H3Africa): Coordinating Center (U24)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-RM-16-017
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.310
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 15th, 2016
Original Application Deadline:	November 15th, 2016
Posted Date:	August 8th, 2016
Creation Date:	August 8th, 2016
Archive Date:	December 16th, 2016
Total Program Funding:	$400,000
Maximum Federal Grant Award:	$400,000
Minimum Federal Grant Award:
Expected Number of Awards:	1
Cost Sharing or Matching:	No
Last Updated:	August 8th, 2016

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations); Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-16-017.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial No...; • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...; • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional); • NIH Directors Early Independence Awards (DP5 Clinical Trial Optional); • NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional); • Using Metabolomics to Investigate Biological Pathways and Networks (R01); • Assay Development for High Throughput Molecular Screening (R21); • Membrane Protein Production and Structure Determination (R01)
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...